Drugs & Targets SU2C, SandboxAQ collaborate to accelerate treatment innovation June 13, 2025Vol.51 No.23
White House At White House forum, Bertagnolli, Califf, Wegrzyn call for greater innovation in clinical trials June 28, 2024Vol.50 No.26By McKenzie Prillaman
Guest Editorial Refocusing cancer R&D for greater impact: Addressing gaps in disparities and access May 31, 2024Vol.50 No.22By Alice L. Pomponio
U.S., Sweden sign cancer research and innovation pact as part of preparedness plan for potential Russian aggression March 22, 2024Vol.50 No.12By Matthew Bin Han Ong
First-ever commercial TIL therapy: How NCI, Iovance, and Moffitt achieved FDA approval February 23, 2024Vol.50 No.08By Matthew Bin Han Ong
Conversation with The Cancer Letter Steven Rosenberg, Friedrich Graf Finckenstein: FDA recognition of TIL therapy is the result of 40 years of research February 23, 2024Vol.50 No.08By Matthew Bin Han Ong
Black History MonthFreeIn the Archives Roderic Pettigrew, founding director of NIBIB, reflects on a career as a “physicianeer”— merging medicine with engineering February 23, 2024Vol.50 No.08By Robert A. Winn and Alexandria Carolan
